- Home
- MCTR vs XLO Comparison
MCTR vs XLO Comparison
Compare MCTR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- XLO
- Stock Information
- Founded
- MCTR 2014
- XLO 2016
- Country
- MCTR Hong Kong
- XLO United States
- Employees
- MCTR N/A
- XLO N/A
- Industry
- MCTR
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- MCTR
- XLO Health Care
- Exchange
- MCTR NYSE
- XLO Nasdaq
- Market Cap
- MCTR 41.0M
- XLO 35.7M
- IPO Year
- MCTR 2025
- XLO 2021
- Fundamental
- Price
- MCTR $1.86
- XLO $0.65
- Analyst Decision
- MCTR
- XLO Buy
- Analyst Count
- MCTR 0
- XLO 1
- Target Price
- MCTR N/A
- XLO $4.00
- AVG Volume (30 Days)
- MCTR 117.4K
- XLO 374.5K
- Earning Date
- MCTR 01-01-0001
- XLO 08-11-2025
- Dividend Yield
- MCTR N/A
- XLO N/A
- EPS Growth
- MCTR N/A
- XLO N/A
- EPS
- MCTR 0.00
- XLO N/A
- Revenue
- MCTR $4,453,234.00
- XLO $9,274,000.00
- Revenue This Year
- MCTR N/A
- XLO $300.08
- Revenue Next Year
- MCTR N/A
- XLO $1.87
- P/E Ratio
- MCTR $1,724.43
- XLO N/A
- Revenue Growth
- MCTR N/A
- XLO N/A
- 52 Week Low
- MCTR $1.86
- XLO $0.62
- 52 Week High
- MCTR $54.91
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- XLO 37.40
- Support Level
- MCTR N/A
- XLO $0.67
- Resistance Level
- MCTR N/A
- XLO $0.72
- Average True Range (ATR)
- MCTR 0.00
- XLO 0.03
- MACD
- MCTR 0.00
- XLO -0.00
- Stochastic Oscillator
- MCTR 0.00
- XLO 25.02
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).